Abstract
Patients with chronic kidney disease (CKD) who are being treated with immunosuppressive medications are at risk for developing Pneumocystis jirovecii pneumonia (PCP). We attempted to characterize the clinical aspects of PCP in CKD patients in order to alert high-risk patients with bad prognosis. A retrospective study of CKD patients was conducted from June 2018 to June 2022. Based on PCP diagnostic criteria, these patients were divided into PCP and non-PCP groups. Using univariate and multivariate logistic regression analysis, risk indicators were evaluated, and nomogram and decision tree were developed. Of the CKD patients screened for Pneumocystis carinii nucleic acid, 1512 were included. Two-hundred forty four (16.14%) were diagnosed with PCP. Of the PCP, 88.5% was receiving glucocorticoid (GC) therapy, of which 66.3% received more than 0.5 mg/kg GC. Multivariate analysis showed that membranous nephropathy (OR 2.35, 95% CI 1.45–3.80), immunosuppressive therapy (OR 1.94, 95% CI 1.06–3.69), and ground glass opacity of CT scanning (OR 1.71, 95% CI 1.10–2.65) were associated with increased risk of Pneumocystis carinii infection. The AUC of nomogram based on logistics regression was 0.78 (0.75–0.81). The mortality in patients with PCP was 32.40%. Univariate analysis and decision tree showed that pulmonary insufficiency (PO2: OR 0.98, 95% CI 0.96–1.00), elevated APTT (OR 1.07, 95% CI 1.04–1.11), and reduced hemoglobin (OR 0.97, 95% CI 0.96–0.98) were associated with poor prognosis. PCP is not rare in CKD patients, particularly in those treated with immunosuppressive therapy. Considering the high mortality of the cases, further studies on the prevention and management of these patients are needed.
Similar content being viewed by others
References
Yang L, Xia P, Zhou Y, Cui Q, Chen G, Zheng K et al (2021) Characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with idiopathic membranous nephropathy. Eur J Clin Microbiol Infect Dis 40(11):2305–2314
Kanj A, Samhouri B, Abdallah N, Chehab O, Baqir M (2021) Host factors and outcomes in hospitalizations for Pneumocystis jirovecii pneumonia in the United States. Mayo Clin Proc 96(2):400–407
Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D (1992) Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267(6):832–837
Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71(1):5–13
Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F et al (2014) Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med 127(12):1242 e11–1242 e17
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100(4):753–779
Lv J, Zhang H, Cui Z, Su T, Zhang Y, Wang H (2008) Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 23(9):2868–2872
Yang CY, Yang AH, Yang WC, Lin CC (2012) Risk factors for Pneumocystis jiroveci pneumonia in glomerulonephritis patients receiving immunosuppressants. Intern Med 51(20):2869–2875
Saito K, Nakayamada S, Nakano K, Tokunaga M, Tsujimura S, Nakatsuka K et al (2004) Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology (Oxford) 43(4):479–485
Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82(9):1052–1059
Sepkowitz KA, Brown AE, Armstrong D (1995) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155(11):1125–1128
Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI et al (2014) Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect 69(1):88–95
Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH et al (2011) Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 55(10):4613–4618
Ye WL, Tang N, Wen YB, Li H, Li MX, Du B et al (2016) Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease. Int Urol Nephrol 48(11):1863–1871
Leth S, Jensen-Fangel S, Ostergaard L, Rostved AA, Jespersen B, Sogaard OS (2014) Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population. Scand J Infect Dis 46(10):704–711
Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V et al (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140(3):167–174
Thomas CF Jr (2004) and A.H. Limper, Pneumocystis pneumonia. N Engl J Med 350(24):2487–2498
Liu CJ, Lee TF, Ruan SY, Yu CJ, Chien JY, Hsueh PR (2019) Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients. Infect Drug Resist 12:1457–1467
Tang G, Tong S, Yuan X, Lin Q, Luo Y, Song H et al (2021) Using routine laboratory markers and immunological indicators for predicting Pneumocystis jiroveci pneumonia in immunocompromised patients. Front Immunol 12:652383
Gaborit BJ, Tessoulin B, Lavergne RA, Morio F, Sagan C, Canet E et al (2019) Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study. Ann Intensive Care 9(1):131
Elsener C, Beeler PE, Battegay E, Bello B, Thienemann F (2020) Risk factors of in-hospital mortality in patients treated for pneumonia at a tertiary care centre in Switzerland. Respiration 99(8):637–645
Berrar and Daniel, Cross-validation. Encycl Bioinformat Computat Biol, 2018.
Lundberg SM and L. SI., A unified approach to interpreting model predictions. In: NIPS’17: Proceedings of the 31st International Conference on Neural Information Processing Systems. (2017). p. 4768–77., 2017.
Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644–649
Mikaelsson L, Jacobsson G, Andersson R (2006) Pneumocystis pneumonia—a retrospective study 1991–2001 in Gothenburg. Sweden. J Infect 53(4):260–265
Pereira-Diaz E, Moreno-Verdejo F, de la Horra C, Guerrero JA, Calderon EJ, Medrano FJ (2019) Changing trends in the epidemiology and risk factors of Pneumocystis pneumonia in Spain. Front Public Health 7:275
Eitner F, Hauser IA, Rettkowski O, Rath T, Lopau K, Pliquett RU et al (2011) Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 26(6):2013–2017
Festic E, Gajic O, Limper AH, Aksamit TR (2005) Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128(2):573–579
Roblot F, Le Moal G, Kauffmann-Lacroix C, Bastides F, Boutoille D, Verdon R et al (2014) Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis 46(3):210–214
Huang L, Fu Q, Ye Y, Lin Y, Yan Q, Chen S (2021) High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther 23(1):232
Zhao Z, Huang Y, Ming B, Zhong J, Dong L (2022) Characterization and associated risk factors of Pneumocystis jirovecii pneumonia in patients with AIRD: a retrospective study. Rheumatology (Oxford) 61(9):3766–3776
van den Brand J, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B et al (2017) Safety of Rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol 28(9):2729–2737
Reid AB, Chen SC, Worth LJ (2011) Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 24(6):534–544
Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338(24):1741–1751
Wang T, Zhang Y, Ping F, Zhao H, Yan L, Lin Q et al (2019) Predicting risk of pulmonary infection in patients with primary membranous nephropathy on immunosuppressive therapy: the AIM-7C score. Nephrology (Carlton) 24(10):1009–1016
Li J, Huang XM, Fang WG, Zeng XJ (2006) Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol 12(3):114–117
Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H (2000) Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118(3):712–720
Li Y, Ghannoum M, Deng C, Gao Y, Zhu H, Yu X et al (2017) Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping. Int J Infect Dis 57:108–115
Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A et al (2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21(4):697–704
Aman J, van der Heijden M, van Lingen A, Girbes AR, van Nieuw Amerongen GP, van Hinsbergh VW et al (2011) Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Crit Care Med 39(1):89–97
Guo F, Chen Y, Yang SL, Xia H, Li XW, Tong ZH (2014) Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One 9(7):e101943
Girndt M, Sester U, Sester M, Kaul H, Kohler H (1999) Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14(12):2807–2810
Yoon JW, Gollapudi S, Pahl MV, Vaziri ND (2006) Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 70(2):371–376
Massry S, Smogorzewski M (2001) Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int Suppl 78:S195–S196
Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A et al (2014) Pneumocystis jirovecii pneumonia in patients with or without AIDS. France. Emerg Infect Dis 20(9):1490–1497
Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC (2014) Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 47(1):42–47
Salzer HJF, Schafer G, Hoenigl M, Gunther G, Hoffmann C, Kalsdorf B et al (2018) Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration 96(1):52–65
Alvaro-Meca A, Palomares-Sancho I, Diaz A, Resino R, De Miguel AG, Resino S (2015) Pneumocystis pneumonia in HIV-positive patients in Spain: epidemiology and environmental risk factors. J Int AIDS Soc 18:19906
Availability of data and materials
Not applicable.
Code availability
Not applicable.
Funding
This work was financially supported by project supported by the National Natural Science Foundation of China (Grant Nos. 82170702, 82230021, 81602104, 82100730, 82200771), Major Research Plan of the National Natural Science Foundation of China (Grant No. 91742204), and National Key R&D Program of China (Grant No. 2021YFC2500200).
Author information
Authors and Affiliations
Contributions
X. Y. C. designed the study, conducted the statistical analyses, and wrote the paper; Y. C. C. contributed to data interpretation and the critical review of the manuscript; S. W. G. and G. X. designed the study, supervised the study process, and contributed to data interpretation and the critical review of the manuscript; and all authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval
The study was approved by the Institutional Ethics Committee of Tongji Hospital. Informed patient consent was waived since the data set of this research consisted of de-identified secondary data.
Consent to participate
All authors agree to participate in this work.
Consent for publication
All authors agree to publish in this work.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cai, XY., Cheng, YC., Ge, SW. et al. Clinical characteristics and risk factor analysis of Pneumocystis jirovecii pneumonia in patients with CKD: a machine learning–based approach. Eur J Clin Microbiol Infect Dis 42, 323–338 (2023). https://doi.org/10.1007/s10096-023-04555-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-023-04555-3